Biologics and Biosimilars Market Size, Share, Growth, and Industry Analysis, By Type (Monoclonal Antibodies, Interferon, Erythropoietin, Insulin, Vaccines and Others) By Application (Tumour, Diabetes, Cardiovascular, Haemophilia and Others), Regional Insights and Forecast From 2026 To 2035

• 

  Download Free Sample to learn more about this report

BIOLOGICS AND BIOSIMILARS MARKET OVERVIEW

The global Biologics and Biosimilars Market is estimated to be valued at approximately USD 244.7 Billion in 2026. The market is projected to reach USD 389.5 Billion by 2035, expanding at a CAGR of 5.3% from 2026 to 2035.

The biologics and biosimilars market is expanding rapidly due to increasing prevalence of chronic diseases, rising biologic drug approvals, and growing adoption of biosimilar therapies across oncology, diabetes, and autoimmune disorders. In 2024, biologics represented 43% of global pharmaceutical product utilization, while biosimilars accounted for 18% of biologic prescriptions worldwide. Monoclonal antibodies dominated with 39% market share because of strong usage in tumor treatment and immunological disorders. More than 780 biologic drugs were commercially available globally during 2024. Biosimilar adoption increased by 29% across hospital systems due to lower treatment costs, improved patient accessibility, and expanding regulatory approvals in developed healthcare markets.

The United States remained the largest biologics and biosimilars market during 2024 due to strong pharmaceutical innovation, advanced healthcare infrastructure, and high chronic disease prevalence. More than 133 biosimilars received regulatory approval in the country by 2024, while biologic therapies represented 46% of specialty drug prescriptions nationwide. Cancer incidence exceeded 2 million diagnosed cases annually, significantly increasing monoclonal antibody demand. Diabetes affected nearly 38 million individuals, supporting insulin biologics utilization across hospitals and clinics. Hospital pharmacies handled 58% of biologic dispensing activity during 2024. Biosimilar penetration increased by 34% in oncology treatment protocols due to expanding physician confidence and formulary inclusion across healthcare institutions.

KEY FINDINGS

LATEST TRENDS

Acquisition Strategies and Partnerships among Key Players to Augment the Market Growth

The biologics and biosimilars market is witnessing substantial transformation due to precision medicine expansion, biosimilar approvals, and increasing adoption of specialty biologic therapies. During 2024, monoclonal antibodies accounted for 39% of biologic treatment utilization because of growing oncology and autoimmune disease applications. Biosimilars represented 18% of total biologic prescriptions globally, reflecting increasing physician acceptance and healthcare cost optimization initiatives. Subcutaneous biologic therapies experienced 27% higher patient preference because of convenient administration compared to intravenous biologics. Personalized biologic therapies represented 33% of new biologic development programs globally during 2024.

Oncology biologics maintained dominant therapeutic demand due to more than 20 million new cancer diagnoses worldwide. Insulin biosimilars also expanded significantly as diabetes prevalence exceeded 537 million affected individuals globally. Hospital pharmacies handled 58% of biologic dispensing activity during 2024 because of complex cold-chain handling requirements and specialist supervision. Artificial intelligence integration improved biologic drug discovery efficiency by 22%, accelerating target identification and clinical development processes. Asia-Pacific also experienced rising biosimilar manufacturing expansion due to increasing pharmaceutical investments and lower production costs. Regulatory agencies globally accelerated biosimilar approvals, supporting stronger market competition and broader patient accessibility.

Download Free Sample to learn more about this report

BIOLOGICS AND BIOSIMILARS MARKET SEGMENTATION

By Type

By type, market is segmented into monoclonal antibodies, interferon, erythropoietin, insulin, vaccines and others. The monoclonal antibodies segment will dominate the market in the coming years.

• Monoclonal Antibodies: Monoclonal antibodies accounted for approximately 39% of global biologics and biosimilars market utilization during 2024 because of extensive use in oncology, rheumatoid arthritis, and autoimmune disorder treatment. More than 140 monoclonal antibody therapies remained commercially available worldwide. Oncology applications represented 52% of monoclonal antibody utilization due to increasing cancer incidence and targeted therapy adoption. Hospital-based biologic administration accounted for 61% of monoclonal antibody treatment activity globally during 2024 because intravenous infusion remains common for oncology biologics. Biosimilar monoclonal antibodies experienced 28% higher prescription adoption across developed healthcare systems. North America and Europe dominated monoclonal antibody consumption because of advanced oncology infrastructure and strong reimbursement systems. 

• Interferon: Interferon biologics represented approximately 11% of global biologic treatment utilization during 2024 due to ongoing applications in multiple sclerosis, hepatitis, and oncology treatment programs. Interferon therapies maintained strong clinical relevance in autoimmune disease management despite increasing competition from newer biologics. Europe accounted for 34% of interferon utilization because of established neurological treatment protocols and advanced specialty care systems. Subcutaneous interferon formulations represented 63% of interferon administration during 2024 because of improved patient convenience and outpatient treatment compatibility. Biosimilar interferon products increased healthcare accessibility by reducing treatment expenses across emerging healthcare systems. Asia-Pacific countries significantly expanded interferon production capabilities due to increasing domestic biologic manufacturing investments and rising neurological disease prevalence.

• Erythropoietin: Erythropoietin biologics accounted for nearly 13% of global biologics utilization during 2024 due to strong demand for anemia treatment associated with chronic kidney disease and cancer therapies. More than 850 million individuals globally suffered from anemia-related conditions during the year, strengthening erythropoietin prescription demand across hospitals and dialysis centers. Hospital pharmacies managed 57% of erythropoietin dispensing activity because dialysis-related treatments require specialized medical supervision. Biosimilar erythropoietin adoption increased by 26% during 2024 across Europe and Asia-Pacific healthcare systems. Improved regulatory approval pathways for biosimilar erythropoietin products also enhanced treatment accessibility within emerging healthcare markets globally.

• Insulin: Insulin biologics represented approximately 17% of global biologics and biosimilars market demand during 2024 because diabetes prevalence exceeded 537 million affected adults worldwide. Long-acting insulin biologics accounted for 49% of insulin therapy utilization due to improved glycemic control and lower dosing frequency. Biosimilar insulin adoption increased by 32% globally during 2024 because healthcare providers focused on improving treatment affordability. North America remained the largest insulin biologics market because diabetes affected nearly 38 million individuals in the United States alone. Hospital and retail pharmacies significantly expanded biosimilar insulin availability during 2024. Smart insulin delivery devices and digital glucose monitoring systems also strengthened biologic insulin treatment adoption among diabetic populations worldwide.

• Vaccines: Vaccines accounted for approximately 14% of biologics utilization during 2024 due to increasing immunization coverage and infectious disease prevention initiatives. More than 5.5 billion vaccine doses were administered globally during the year across public healthcare systems and immunization campaigns. Recombinant biologic vaccines represented 46% of advanced vaccine development programs globally. Asia-Pacific remained a major vaccine production center because of extensive public immunization infrastructure and expanding biologic manufacturing capabilities. Pediatric vaccination programs significantly contributed to biologic vaccine demand across developing economies. Biologic vaccine innovations focusing on mRNA technologies and recombinant protein platforms also expanded pharmaceutical research activities during 2024.

• Others: Other biologics including growth hormones, coagulation factors, and enzyme replacement therapies accounted for approximately 6% of market utilization during 2024. Hemophilia biologics represented 41% of this category due to increasing clotting factor therapy adoption globally. Rare disease biologics gained increasing healthcare attention because over 300 million individuals globally were affected by rare disorders. Advanced recombinant technologies improved biologic production efficiency by 19% during 2024, supporting broader accessibility for niche biologic therapies. Specialty hospital networks expanded rare disease treatment programs, increasing utilization of advanced biologic products. Biosimilar development also expanded into niche therapeutic categories including growth hormones and enzyme replacement therapies globally.

By Application

Based on applications, the market is classified into tumor, diabetes, cardiovascular, hemophilia and others. The tumor segment will lead the global share through forecast period.

• Tumor: Tumor applications dominated the biologics and biosimilars market with approximately 36% share during 2024 due to increasing cancer prevalence and targeted therapy adoption. More than 20 million new cancer cases were diagnosed globally, significantly increasing monoclonal antibody demand. Oncology biosimilars represented 42% of new biosimilar approvals during 2024 because healthcare systems focused on improving cancer treatment affordability. Hospital oncology centers managed 68% of biologic tumor therapy administration because infusion-based treatments require specialized medical supervision. Personalized oncology biologics improved treatment response precision by 24% during 2024. North America and Europe remained leading tumor biologics markets because of advanced oncology infrastructure and strong reimbursement systems.

• Diabetes: Diabetes applications accounted for approximately 24% of biologic market demand during 2024 because global diabetes prevalence exceeded 537 million affected adults. Insulin biologics dominated diabetes treatment utilization, while biosimilar insulin products increased prescription penetration by 32% globally. North America represented 37% of insulin biologic utilization because diabetes affected nearly 38 million individuals in the United States. Smart insulin pens and continuous glucose monitoring integration improved treatment adherence by 21% during 2024. Asia-Pacific also experienced strong diabetes biologic demand because urbanization and lifestyle-related metabolic disorders increased rapidly across China and India. Hospital and retail pharmacies significantly expanded biologic insulin availability during the year.

• Cardiovascular: Cardiovascular applications represented approximately 14% of biologic utilization during 2024 due to increasing prevalence of heart disease and cholesterol-related disorders. Cardiovascular diseases caused nearly 17.9 million deaths globally during the year, supporting demand for biologic therapies targeting lipid disorders and thrombotic conditions. Monoclonal antibody therapies for cholesterol management increased by 23% across specialty cardiovascular clinics during 2024. North America remained a leading market because obesity and hypertension prevalence remained significantly high. Biosimilar cardiovascular biologics also improved patient accessibility across Europe and Asia-Pacific healthcare systems.

• Hemophilia: Hemophilia applications accounted for approximately 9% of biologics utilization during 2024 due to increasing coagulation factor therapy adoption. More than 830,000 individuals globally were diagnosed with hemophilia disorders during the year. Recombinant clotting factor biologics represented 71% of hemophilia therapy utilization because of improved treatment safety and effectiveness. Specialty treatment centers handled 74% of hemophilia biologic administration globally during 2024. Gene therapy research and extended half-life biologic factors also expanded innovation within hemophilia treatment programs. Europe maintained strong hemophilia biologic adoption because of advanced rare disease healthcare infrastructure.

• Others: Other applications including autoimmune disorders, neurological diseases, and rare genetic conditions represented approximately 17% of biologics utilization during 2024. Autoimmune disease biologics experienced 27% higher prescription demand because rheumatoid arthritis and psoriasis prevalence continued increasing globally. Biologic therapies for neurological disorders also expanded significantly across specialty healthcare institutions. Hospital pharmacies handled 59% of specialty biologic dispensing within autoimmune and neurological treatment programs. Emerging precision medicine technologies further strengthened biologic utilization across personalized treatment applications globally.

MARKET DYNAMICS

Driving Factor

Increasing prevalence of chronic and autoimmune diseases.

The rising prevalence of cancer, diabetes, rheumatoid arthritis, and autoimmune disorders remains the primary growth driver for the biologics and biosimilars market. During 2024, more than 20 million new cancer cases were diagnosed globally, significantly increasing monoclonal antibody demand. Diabetes affected approximately 537 million adults worldwide, strengthening insulin biologic utilization across hospitals and specialty clinics. Biologic therapies represented 43% of specialty pharmaceutical utilization globally because of strong clinical effectiveness in chronic disease management. Biosimilar adoption increased by 29% across healthcare institutions due to physician acceptance and healthcare cost optimization programs. Hospital pharmacies handled 58% of biologic dispensing activity because biologic products require specialized handling and administration procedures. Personalized medicine programs also increased biologic utilization rates among oncology and immunology patients globally during 2024.

Restraining Factor

Complex manufacturing and regulatory compliance requirements.

Biologic and biosimilar manufacturing complexity remains a major restraint affecting market expansion. Approximately 39% of pharmaceutical companies identified biologic production consistency and regulatory compliance as major operational challenges during 2024. Biologic manufacturing facilities require advanced sterile environments, specialized bioreactors, and cold-chain logistics systems, increasing operational complexity significantly. Regulatory approval procedures for biosimilars remained extensive because of stringent clinical comparability and safety evaluation requirements. Around 47% of healthcare providers also expressed concerns regarding biosimilar interchangeability and long-term therapeutic equivalence. Cold-chain transportation and biologic storage expenses increased by 16% during 2024 due to rising pharmaceutical logistics requirements. Intellectual property disputes and patent litigation further delayed biosimilar market entry across several therapeutic categories globally.

Expansion of biosimilar adoption across emerging healthcare systems.

Opportunity

Emerging healthcare systems present strong growth opportunities for biologics and biosimilars manufacturers due to rising healthcare investments and increasing chronic disease prevalence. Biosimilar prescriptions increased by 31% across Asia-Pacific and Latin American healthcare institutions during 2024 due to improving affordability and expanding insurance coverage. Government healthcare agencies increasingly promoted biosimilar substitution programs to improve patient accessibility and reduce pharmaceutical expenditure. Oncology biosimilars represented 42% of new biosimilar approvals globally because cancer treatment demand continues expanding rapidly.

High development costs and supply chain sensitivity.

Challenge

The biologics and biosimilars market faces major challenges related to manufacturing expenses, cold-chain logistics, and supply chain disruptions. Biologic production requires sophisticated fermentation systems, sterile processing technologies, and advanced quality control infrastructure. Cold-chain transportation costs increased by 16% globally during 2024 because biologic products require strict temperature-controlled distribution systems. Supply chain instability affected raw material availability for biologic manufacturing, particularly cell culture media and specialized bioprocessing materials. Around 41% of pharmaceutical manufacturers reported production delays caused by global supply chain disruptions.

• Download Free Sample to learn more about this report

•  

BIOLOGICS AND BIOSIMILARS MARKET REGIONAL INSIGHTS

• North America

North America accounted for approximately 41% of global biologics and biosimilars market utilization during 2024 due to advanced pharmaceutical infrastructure, high specialty drug adoption, and increasing chronic disease prevalence. The United States remained the dominant regional market with more than 133 approved biosimilars and over 2 million annual cancer diagnoses. Biologic therapies represented 46% of specialty pharmaceutical prescriptions nationwide during the year. Hospital pharmacies managed 58% of biologic dispensing activity across North America because biologic products require specialized storage and administration. Oncology biologics represented 39% of regional biologic utilization due to rising targeted cancer therapy adoption.

Biosimilar prescription penetration increased by 34% across oncology treatment protocols because healthcare systems focused on reducing specialty treatment expenses. Diabetes prevalence exceeded 38 million affected individuals in the United States, strengthening insulin biologic utilization across hospitals and retail pharmacies. Canada also expanded biosimilar reimbursement programs, improving treatment accessibility within public healthcare systems. Artificial intelligence integration improved biologic drug discovery efficiency by 22% across pharmaceutical research institutions. Cold-chain pharmaceutical infrastructure expansion and increasing biologic clinical trials further strengthened regional market leadership during 2024.

• Europe

Europe represented approximately 29% of the global biologics and biosimilars market during 2024 because of extensive biosimilar adoption, strong healthcare reimbursement frameworks, and advanced regulatory pathways. Germany, France, Italy, and the United Kingdom remained leading regional markets due to increasing oncology biologic utilization and autoimmune disease treatment demand. Biosimilars accounted for 31% of biologic prescriptions across European hospitals during 2024. The European region approved more than 90 biosimilar products by 2024, significantly improving patient access to specialty therapies. Monoclonal antibodies represented 41% of biologic utilization because cancer incidence and autoimmune disorder prevalence continued increasing.

Hospital treatment centers managed 63% of biologic administration due to widespread infusion-based therapies and specialist care infrastructure. Government healthcare agencies promoted biosimilar substitution programs, increasing prescription adoption by 28% during 2024. Interferon biologics maintained strong demand across multiple sclerosis treatment programs within Western Europe. Cold-chain pharmaceutical logistics networks expanded by 18% across the region, supporting broader biologic distribution efficiency. Eastern European healthcare systems also increased biosimilar procurement due to growing healthcare modernization investments and chronic disease treatment demand.

• Asia-Pacific

Asia-Pacific accounted for approximately 23% of global biologics and biosimilars market activity during 2024 and emerged as a major biologic manufacturing center due to increasing pharmaceutical investments and expanding healthcare access. China, Japan, India, and South Korea led regional biologic utilization because of rising chronic disease prevalence and improving specialty healthcare infrastructure. Biosimilar prescription adoption increased by 31% across Asia-Pacific healthcare institutions during 2024 due to lower treatment costs and expanding government healthcare coverage. China significantly expanded domestic biologic production capabilities, while India remained a major biosimilar export hub with over 70 manufacturing facilities producing biologic therapies.

Diabetes prevalence across Asia-Pacific exceeded 290 million affected adults during 2024, strengthening insulin biologic utilization across hospitals and clinics. Oncology biologics represented 35% of regional biologic prescriptions because cancer incidence continued increasing rapidly. Hospital pharmacies managed 54% of biologic distribution activity due to cold-chain handling requirements and specialist supervision. Japan maintained strong monoclonal antibody demand due to advanced oncology treatment adoption, while South Korea expanded biologic research and development investments by 19% during 2024. Government initiatives supporting local biologic manufacturing and biosimilar approvals significantly improved regional pharmaceutical competitiveness and healthcare accessibility.

• Middle East & Africa

Middle East & Africa represented approximately 7% of global biologics and biosimilars market activity during 2024 due to improving healthcare infrastructure and increasing chronic disease management programs. Saudi Arabia, South Africa, and the United Arab Emirates remained leading regional biologic markets because of expanding specialty healthcare services and rising pharmaceutical investments. Cancer incidence increased by 16% across Middle Eastern healthcare systems during 2024, supporting stronger monoclonal antibody therapy adoption. Biosimilar utilization increased by 21% across regional hospitals because healthcare providers focused on improving treatment affordability and patient access. Hospital pharmacies handled 61% of biologic distribution activity due to specialized cold-chain storage requirements.

Diabetes prevalence exceeded 73 million affected individuals across the Middle East and Africa during 2024, significantly increasing insulin biologic demand. Government healthcare modernization programs expanded biologic procurement activities within public hospital systems. International pharmaceutical companies also strengthened biologic distribution partnerships to improve specialty drug availability across urban healthcare centers. South Africa expanded biosimilar oncology treatment programs during 2024 due to rising cancer treatment demand and healthcare investment growth. The Gulf region experienced increasing adoption of advanced biologic therapies because of improving healthcare expenditure allocation and rising specialty physician availability.

LIST OF TOP BIOLOGICS AND BIOSIMILARS COMPANIES

• Roche
• Amgen
• AbbVie
• Sanofi-Aventis
• Johnson & Johnson
• Pfizer
• Novo Nordisk
• Eli Lilly
• Novartis
• Merck
• 3sbio
• Changchun High Tech
• CP Guojian
• Biotech
• Gelgen
• Innovent
• Dong Bao
• Ganlee
• United Laboratories

Top 2 Companies With Highest Market Share

• Roche: Accounted for approximately 18% of global biologics utilization during 2024.
• AmgenRepresented nearly 13% of global biologics and biosimilars market share during 2024.

INVESTMENT ANALYSIS AND OPPORTUNITIES

The biologics and biosimilars market continues attracting significant global investment due to increasing chronic disease prevalence, expanding biosimilar approvals, and rising biologic therapy adoption across specialty healthcare systems. During 2024, biologics represented 43% of specialty pharmaceutical utilization globally, strengthening investments in biologic manufacturing facilities and advanced bioprocessing technologies. Asia-Pacific emerged as a major investment destination because biosimilar prescription adoption increased by 31% across regional healthcare institutions. China and India significantly expanded biologic manufacturing infrastructure, while South Korea increased biologic research investments by 19% during 2024. Artificial intelligence integration improved biologic drug discovery efficiency by 22%, encouraging pharmaceutical companies to invest in precision medicine platforms and digital biotechnology solutions.

Oncology biologics represented 36% of therapeutic biologic demand globally, supporting investment opportunities in monoclonal antibody production and targeted cancer therapy development. Biosimilar insulin products also experienced 32% higher prescription penetration, creating opportunities for affordable diabetes treatment manufacturing expansion. Cold-chain pharmaceutical logistics infrastructure expanded by 18% globally during 2024 to support biologic transportation requirements. Government healthcare systems increasingly promoted biosimilar procurement strategies to improve specialty treatment accessibility. Personalized medicine programs, subcutaneous biologic formulations, and advanced recombinant technologies also generated strong investment opportunities across biologic and biosimilar research pipelines.

NEW PRODUCT DEVELOPMENT

Biologics and biosimilars manufacturers increasingly focused on personalized medicine, subcutaneous formulations, and advanced recombinant technologies during 2024. Personalized biologic therapies represented 33% of new biologic development programs because healthcare systems increasingly prioritized targeted treatment precision. Monoclonal antibody innovations remained dominant due to strong oncology and autoimmune disorder treatment demand. Subcutaneous biologic therapies experienced 27% higher patient preference compared to intravenous formulations because of convenient administration and reduced hospital visits. Biosimilar monoclonal antibodies represented 42% of new biosimilar approvals globally during 2024 due to increasing oncology treatment accessibility initiatives. Artificial intelligence-assisted drug discovery improved biologic target identification efficiency by 22%, accelerating pharmaceutical development timelines.

Long-acting insulin biologics accounted for 49% of insulin therapy innovations because diabetic patients increasingly preferred lower dosing frequency and improved glycemic control. Recombinant vaccine technologies also expanded rapidly due to increasing infectious disease prevention programs and advanced biologic manufacturing capabilities. Biologic drug-device combination products, including smart injection pens and wearable delivery systems, strengthened patient treatment adherence across diabetes and autoimmune disease applications. Pharmaceutical companies additionally invested in extended half-life biologics and gene-engineered recombinant proteins to improve therapeutic effectiveness and reduce treatment frequency. Cold-chain packaging innovations improved biologic transportation stability by 18% during 2024, supporting broader international distribution capabilities.

FIVE RECENT DEVELOPMENTS (2023-2025)

• In 2025, biosimilar oncology therapies represented 42% of global biosimilar approvals due to increasing cancer treatment accessibility initiatives worldwide.
• In 2024, subcutaneous biologic therapies recorded 27% higher patient preference because of convenient administration and reduced hospital dependency.
• In 2024, artificial intelligence integration improved biologic drug discovery efficiency by 22%, accelerating pharmaceutical target identification and clinical development processes.
• In 2024, biosimilar insulin adoption increased by 32% globally as healthcare systems expanded affordable diabetes treatment programs.
• In 2023, more than 90 biosimilar products received approvals across European healthcare markets, strengthening specialty drug accessibility and physician adoption rates.

REPORT COVERAGE OF BIOLOGICS AND BIOSIMILARS MARKET

The biologics and biosimilars market report provides extensive analysis of biologic drug utilization, biosimilar adoption trends, therapeutic applications, and pharmaceutical manufacturing developments across global healthcare systems. The report evaluates more than 780 commercially active biologic therapies during 2024 while examining biosimilar approvals, prescription penetration, and treatment accessibility across oncology, diabetes, cardiovascular, and autoimmune disease applications. Monoclonal antibodies accounted for 39% of biologic utilization globally and are comprehensively analyzed according to oncology demand, personalized medicine expansion, and biosimilar competition. The report also examines insulin biologics, interferons, erythropoietin products, recombinant vaccines, and advanced rare disease biologics based on clinical utilization and healthcare infrastructure development.

Application analysis covers tumor therapies, diabetes treatment, cardiovascular disorders, hemophilia management, and specialty biologic therapies. Tumor applications represented 36% of biologic demand because cancer incidence exceeded 20 million new diagnoses globally during 2024. Regional analysis evaluates North America, Europe, Asia-Pacific, and Middle East & Africa based on biosimilar approvals, healthcare expenditure, pharmaceutical manufacturing capacity, and specialty treatment accessibility. The report additionally covers biologic drug innovation, artificial intelligence integration, cold-chain logistics, biosimilar procurement programs, and personalized medicine developments. Competitive analysis evaluates leading pharmaceutical manufacturers according to biologic portfolios, biosimilar commercialization strategies, and advanced recombinant technology investments across global healthcare markets.